- The product developed by Pfizer and BioNTech is 90% effective, the producer says. The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.
- Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.
- After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the Data Monitoring Committee performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose.
- Pfizer says there are no serious side effects. If key indicators are safe, the world may have a tool to tackle the pandemic in a week.
- The European Commission has already agreed to sign an agreement with the developers on the purchase of 300 million doses of the coronavirus vaccine.
Zelensky asks Merkel to assist in allocating COVID-19 vaccine to Ukraine

The parties agreed to further coordinate efforts to overcome the consequences of the pandemic.
President of Ukraine Volodymyr Zelensky on November 10 had a phone call with Germany's Chancellor Angela Merkel during which he asked the German leader to assist in supplying a U.S.-German-developed COVID-19 vaccine to Ukraine.
"We welcome the breakthrough achieved by the German company BioNTech together with the American company Pfizer in the development of a coronavirus vaccine. This is very encouraging news. I would like to ask for your assistance in taking into account the interests of Ukraine when planning the supply of COVID-19 vaccine," Zelensky said, according to the press service of the Ukrainian President's Office.
Pfizer vaccine
Latest news
Latest newsGeorgia’s Constitutional Court Continues Case on Banning Opposition Parties: Political Pluralism at Stake
12.Oct.2026
Azerbaijan and Iran Step Up Security Contacts Amid Hijab Protests
12.Oct.2026
Personnel Shortages Complicate Ukrainian Forces’ Rotation: Ukraine Faces Long-Term Challenges on the Front Line
11.Oct.2026
Trump Eases Sanctions on Russian Fuel After Talks with Putin: Kyiv Fears Boost to Moscow’s War Revenues
10.Oct.2026
Putin Seeks to Strengthen Russia’s Influence in the Post-Soviet Space Through the CIS
10.Oct.2026
Russia and the South Caucasus: External Pressure, Political Competition and a Crisis of Trust
10.Oct.2026
Peaceful Settlement Between Armenia and Azerbaijan: Moving from Declarations to Implementation
10.Oct.2026
Moldova Ready to Accept as Many Ukrainians as Necessary if Situation Worsens This Winter
09.Oct.2026
Turkmenistan Turns Avaza into a Regional Diplomatic Hub as Caspian, Central Asian and CIS Agendas Converge
08.Oct.2026
Romania Scrambles Spanish F-18s After Aerial Targets Detected Near Ukrainian Border
07.Oct.2026
Berlin Deepens Defence Partnership with Kyiv: Germany to Provide Ukraine with €1 Billion in Military Aid
07.Oct.2026
European Parliament Against Georgian Dream: EU Prepares New Response to Tbilisi
06.Oct.2026
Bulgarian Foreign Minister to Discuss European Security and International Law in the Netherlands
05.Oct.2026
Rheinmetall in Bulgaria: Sofia Emerges as a New NATO Defence-Industrial Hub in the Balkans
05.Oct.2026
The Cost of a Long War: Moscow Expands Spending Plans Through 2029
05.Oct.2026

13 Oct 2026


